Gwoo S, et al. - In this study, researchers searched for the predictors of hyperkalemia risk following hypertension control using aldosterone blockade in the presence or absence of chronic kidney disease (CKD). As per observations, selected CKD patients well-tolerated spironolactone. The risk of serious hyperkalemia or a significant reduction of eGFR appears to be low. They recommended strict monitoring over the first month of treatment followed by standard surveillance for angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.